https://www.selleckchem.com/pr....oducts/3-methyladeni
76; 95% confidence interval (95% CI) 0.56-1.01; p=0.06) (heterogeneity I =34%). We recorded 222 adverse events in 2,742 patients treated with bemiparin and 288 adverse events in 2,731 patients treated with enoxaparin (8.1 vs. 10.5 adverse events per 100 patients, respectively; p=0.003). However, the meta-analysis for safety showed a significant heterogeneity making not possible to pool the result across the trials. Bemiparin proved a non-inferior efficacy compared to enoxaparin with a significant reduction in adverse events per
Like
Comment
Share
